MX2012012925A - Regimen de dosificacion de derivados de sulfuro de diarilo. - Google Patents
Regimen de dosificacion de derivados de sulfuro de diarilo.Info
- Publication number
- MX2012012925A MX2012012925A MX2012012925A MX2012012925A MX2012012925A MX 2012012925 A MX2012012925 A MX 2012012925A MX 2012012925 A MX2012012925 A MX 2012012925A MX 2012012925 A MX2012012925 A MX 2012012925A MX 2012012925 A MX2012012925 A MX 2012012925A
- Authority
- MX
- Mexico
- Prior art keywords
- 4alkyl
- 4alkoxy
- halogen
- phenyl
- formula
- Prior art date
Links
- -1 diaryl sulfide derivatives Chemical class 0.000 title abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000006372 monohalo methyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162082 | 2010-05-06 | ||
| PCT/EP2011/057210 WO2011138398A1 (en) | 2010-05-06 | 2011-05-05 | Dosage regimen of diaryl sulfide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012012925A true MX2012012925A (es) | 2012-12-17 |
Family
ID=42236590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012012925A MX2012012925A (es) | 2010-05-06 | 2011-05-05 | Regimen de dosificacion de derivados de sulfuro de diarilo. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20130210924A1 (enExample) |
| EP (1) | EP2566473B1 (enExample) |
| JP (3) | JP2013525469A (enExample) |
| KR (1) | KR20130098885A (enExample) |
| CN (2) | CN102917698A (enExample) |
| AU (1) | AU2011249789B2 (enExample) |
| BR (1) | BR112012028248A2 (enExample) |
| CA (1) | CA2794607A1 (enExample) |
| EA (1) | EA201201515A1 (enExample) |
| ES (1) | ES2562416T3 (enExample) |
| MX (1) | MX2012012925A (enExample) |
| WO (1) | WO2011138398A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI519539B (zh) | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
| AU2014220377B2 (en) | 2013-02-20 | 2017-05-04 | Priothera Limited | Treatment of graft versus host disease in transplant patients |
| EP4438037A1 (en) * | 2021-01-28 | 2024-10-02 | Priothera SAS | Methods of treatment with s1p receptor modulators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100913269B1 (ko) * | 2001-09-27 | 2009-08-21 | 교린 세이야꾸 가부시키 가이샤 | 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제 |
| JP4152884B2 (ja) | 2001-09-27 | 2008-09-17 | 杏林製薬株式会社 | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 |
| JP4571497B2 (ja) * | 2002-09-19 | 2010-10-27 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| DK1602660T3 (da) | 2003-02-18 | 2011-05-23 | Kyorin Seiyaku Kk | Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer |
| EP1660449B1 (en) | 2003-08-28 | 2009-11-18 | Novartis AG | Aminopropanol derivatives |
| CN101905023B (zh) * | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
| JPWO2006041015A1 (ja) * | 2004-10-12 | 2008-05-15 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| EP2384749A1 (en) * | 2004-11-29 | 2011-11-09 | Novartis AG | Dosage regimen of an S1P receptor agonist |
| NZ566137A (en) * | 2005-09-09 | 2011-05-27 | Novartis Ag | The use of diphenyl thioether derivatives to treat autoimmune diseases |
| CA2716448A1 (en) * | 2008-03-17 | 2009-09-24 | Patrick Brossard | Dosing regimen for a selective s1p1 receptor agonist |
| CA2734585A1 (en) * | 2008-08-18 | 2010-02-25 | Novartis Ag | Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| US20100160259A1 (en) * | 2008-12-22 | 2010-06-24 | Robert Schmouder | Dosage regimen for a s1p receptor agonist |
| MX367667B (es) * | 2008-12-22 | 2019-08-30 | Novartis Ag | Régimen de dosificación de un agonista de los receptores de s1p. |
-
2011
- 2011-05-05 WO PCT/EP2011/057210 patent/WO2011138398A1/en not_active Ceased
- 2011-05-05 BR BR112012028248A patent/BR112012028248A2/pt not_active IP Right Cessation
- 2011-05-05 ES ES11720419.8T patent/ES2562416T3/es active Active
- 2011-05-05 CN CN2011800227113A patent/CN102917698A/zh active Pending
- 2011-05-05 CN CN201610590854.9A patent/CN106309416A/zh active Pending
- 2011-05-05 CA CA2794607A patent/CA2794607A1/en not_active Abandoned
- 2011-05-05 AU AU2011249789A patent/AU2011249789B2/en not_active Expired - Fee Related
- 2011-05-05 JP JP2013508506A patent/JP2013525469A/ja not_active Withdrawn
- 2011-05-05 US US13/643,324 patent/US20130210924A1/en not_active Abandoned
- 2011-05-05 KR KR1020127031867A patent/KR20130098885A/ko not_active Withdrawn
- 2011-05-05 MX MX2012012925A patent/MX2012012925A/es not_active Application Discontinuation
- 2011-05-05 EP EP11720419.8A patent/EP2566473B1/en active Active
- 2011-05-05 EA EA201201515A patent/EA201201515A1/ru unknown
-
2014
- 2014-07-28 US US14/341,891 patent/US20140336265A1/en not_active Abandoned
-
2016
- 2016-04-14 JP JP2016081108A patent/JP6290963B2/ja not_active Expired - Fee Related
- 2016-10-19 US US15/297,683 patent/US20170119702A1/en not_active Abandoned
-
2017
- 2017-12-07 US US15/834,482 patent/US20180161290A1/en not_active Abandoned
-
2018
- 2018-02-08 JP JP2018020950A patent/JP6615247B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018100280A (ja) | 2018-06-28 |
| JP6615247B2 (ja) | 2019-12-04 |
| US20180161290A1 (en) | 2018-06-14 |
| US20140336265A1 (en) | 2014-11-13 |
| WO2011138398A1 (en) | 2011-11-10 |
| CN106309416A (zh) | 2017-01-11 |
| US20170119702A1 (en) | 2017-05-04 |
| KR20130098885A (ko) | 2013-09-05 |
| JP2016183159A (ja) | 2016-10-20 |
| JP2013525469A (ja) | 2013-06-20 |
| AU2011249789A1 (en) | 2012-12-13 |
| CA2794607A1 (en) | 2011-11-10 |
| JP6290963B2 (ja) | 2018-03-07 |
| ES2562416T3 (es) | 2016-03-04 |
| AU2011249789B2 (en) | 2015-03-19 |
| US20130210924A1 (en) | 2013-08-15 |
| BR112012028248A2 (pt) | 2016-08-02 |
| EP2566473B1 (en) | 2016-01-06 |
| EP2566473A1 (en) | 2013-03-13 |
| CN102917698A (zh) | 2013-02-06 |
| EA201201515A1 (ru) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| PE20181519A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| BRPI0508461A (pt) | diaminopirimidinas como antagonistas de p2x3 e p2x2/3 | |
| PE20140099A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| NZ592880A (en) | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| AR070158A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa | |
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| IL199077A (en) | Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| AR068919A1 (es) | 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales. | |
| MX2014003701A (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
| GEAP201813485A (en) | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
| EA201101211A1 (ru) | 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-l-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh и его применение для лечения легочных заболеваний | |
| BRPI0518949A2 (pt) | composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica | |
| EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |